Product image of Medi-Mibi (Technetium (99mtc) Sestamibi) supplied by GNH India

Medi-Mibi

Active Ingredient:
Technetium (99mtc) Sestamibi
Origin:
EU

Medi-Mibi (Technetium (99mtc) Sestamibi)

Technetium (99mTc) sestamibi, the active ingredient in Medi-Mibi, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed for myocardial perfusion imaging and cardiac stress testing in patients undergoing evaluation of coronary artery disease.

GNH India supplies Medi-Mibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, cardiac imaging centres and diagnostic clinics worldwide.

Manufacturer / TM Owner

Radiopharmacy Laboratórium Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Medi-Mibi is used in cardiac imaging to assess myocardial blood flow and detect ischemia.
  • Myocardial perfusion imaging: provides visual assessment of regional blood flow to identify areas of reduced perfusion.
  • Cardiac stress testing: enables evaluation of heart function under pharmacologic or exercise stress conditions.
  • Coronary artery disease assessment: helps detect obstructive lesions by highlighting perfusion defects.
  • Evaluation of ventricular function: assists in quantifying left ventricular ejection fraction during gated SPECT studies.

How It Works

  • Technetium‑99m sestamibi is a lipophilic cationic complex that diffuses passively into myocardial cells in proportion to regional blood flow. Once inside, it binds to mitochondrial membranes and remains trapped, emitting gamma photons that are captured by a gamma camera to produce scintigraphic images of myocardial perfusion.

Side Effects

Medi-Mibi may cause a range of adverse reactions following intravenous administration.

Common Side Effects

  • Injection site pain: mild discomfort at the site of administration.
  • Nausea: transient feeling of queasiness.
  • Headache: mild to moderate headache.
  • Flushing: temporary warmth or redness of the skin.

Serious or Rare Side Effects

  • Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention.
  • Radiation‑induced skin injury: localized skin changes at high exposure sites.
  • Severe hypotension: marked drop in blood pressure, potentially requiring intervention.

Precautions & Warnings

  • Prior to using Medi-Mibi, consider the following safety measures.
  • Pregnancy: assess risk versus benefit; use only if essential for maternal care.
  • Breastfeeding: consider discontinuing nursing or evaluate infant exposure risk.
  • Renal impairment: monitor because reduced clearance may increase radiation exposure.
  • Thyroid disorders: avoid in patients with hyperthyroidism due to possible tracer uptake.
  • Radiation safety: follow institutional protocols to limit staff and patient exposure.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Medi-Mibi may interact with other agents that affect tracer distribution or radiation exposure.

Major Interactions (Avoid)

  • Thyroid blocking agents (e.g., potassium iodide): may alter biodistribution of the tracer.
  • Other radiopharmaceuticals administered within 24 h: can lead to cumulative radiation dose.
  • Chemotherapeutic agents affecting mitochondrial function: may interfere with tracer uptake.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt heart‑rate response during stress testing.
  • Calcium channel blockers: may influence myocardial perfusion patterns.
  • Sedatives: can affect patient cooperation during image acquisition.

Frequently Asked Questions

Medi-Mibi is a radiopharmaceutical used primarily for myocardial perfusion imaging and cardiac stress testing. It helps clinicians visualize blood flow to the heart muscle, detect areas of reduced perfusion, and assess coronary artery disease during nuclear medicine procedures.

Technetium‑99m sestamibi is a lipophilic cation that enters heart cells proportionally to blood flow and binds to mitochondrial membranes. The radioactive technetium emits gamma photons, which are captured by a gamma camera to create detailed images of myocardial perfusion.

The dose of Medi-Mibi is determined by the prescribing physician based on the specific imaging protocol, patient weight, and clinical indication. Healthcare providers calculate the appropriate activity to achieve optimal image quality while minimizing radiation exposure.

Safety data for Medi-Mibi in pregnancy and lactation are limited. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and appropriate precautions should be taken in consultation with a specialist.

To order Medi-Mibi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Medi-Mibi (Technetium‑99m sestamibi) offers high myocardial uptake and rapid clearance, providing clear perfusion images. Compared with agents like thallium‑201, it delivers better image quality, lower radiation dose, and a shorter imaging protocol, making it a preferred choice for many nuclear cardiology labs.

Medi-Mibi must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Use aseptic techniques during preparation, and follow local radiation safety guidelines for handling and disposal.

Medi-Mibi is administered intravenously as a sterile solution. The injection is performed by qualified healthcare personnel, typically immediately before the imaging session, and the patient is then positioned for gamma‑camera acquisition according to the imaging protocol.

Serious risks include rare allergic reactions such as anaphylaxis, radiation‑induced skin injury at high exposure sites, and severe hypotension. Prompt recognition and management of these events are essential, and patients should be monitored according to institutional safety procedures.

Medi-Mibi should be avoided in patients with known severe allergic reactions to technetium‑based agents, uncontrolled thyroid disorders, or those for whom the radiation exposure outweighs the diagnostic benefit. Clinical judgment is required to identify contraindications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Technetium (99mtc) Sestamibi

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT